Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01530256 · ClinicalTrials.gov registry record · Phase 1
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
A Phase 1 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01530256 is a Phase 1 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 3 participants.
The verdict
NCT01530256, a Phase 1 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.
Interventions
- BIOLOGICAL ALD518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01530256
The ClinicalTrials.gov registry entry for NCT01530256 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALD518 is the first listed.
NCT01530256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01530256 about?
NCT01530256 is a clinical study titled "Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)". The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.
What is the current status of trial NCT01530256?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01530256?
The interventions under investigation include: ALD518 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01530256?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.